You have 9 free searches left this month | to do more
Showing 1 - 25 of
>10,000 items
Trials Per Page
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
S
Avelumab in Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma[AVENT STUDY]
Active, not recruiting
  • Lymphoma, Extranodal NK-T-Cell
  • Seoul, Korea, Republic of
    81, Irwon-ro, Gangnam-gu, Seoul, Republic of Korea
2021-09-22
Sep 22, 2021
I
Pembrolizumab and Radiotherapy for Patients With NK/T Cell Lymphoma
Recruiting
  • Lymphoma, Extranodal NK-T-Cell
  • Shanghai, China
    Shanghai Rui-Jin Hospital
2022-03-29
Mar 29, 2022
N
Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas - 2021
Completed
Has Results
  • Lymphoma, T-Cell
  • Lymphoma, Extranodal NK-T-Cell
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
2022-02-03
Feb 3, 2022
N
T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas - 2022
Completed
  • Lymphoma, Large-Cell, Anaplasitc
  • +4 more
  • Anti-CD30-CAR T cells
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
2022-01-27
Jan 27, 2022
C
Anti-PD-1 Antibody and P-GEMOX Chemotherapy Combined With Radiotherapy in High-risk Early-Stage ENKTL
Recruiting
  • Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type
  • +2 more
  • Anti-PD-1 monoclonal antibody
  • +4 more
  • Beijing, Beijing, China
    National Cancer Center/Cancer Hospital, Chinese Academy of Medic
2022-02-23
Feb 23, 2022
C
Radiotherapy and Anti-PD-1 in Low-risk ES-ENKTCL
Recruiting
  • Early-stage
  • Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type
  • Anti-PD-1 monoclonal antibody
  • Beijing, Beijing, China
    National Cancer Center/National Clinical Research Center for Can
2021-12-07
Dec 7, 2021
R
Social Media-based Active Self-report on Incidence and Outcomes of Adverse Events in NK/TCL Patients - 2021
Completed
  • Extranodal NK-T-Cell Lymphoma, Nasal Type
  • L-Asparaginase or or Pegaspargase containing chemotherapy
  • Beijing, Beijing, China
  • +1 more
2021-09-13
Sep 13, 2021
R
MESA Versus ESA in the Treatment of Early Stage NK/T-cell Lymphoma
Active, not recruiting
  • Extranodal NK/T-cell Lymphoma, Nasal Type
  • Shanghai, Shanghai, China
    Ruijin Hospital
2021-08-19
Aug 19, 2021
H
PEG-ASP+Gemox Regimen and Thalidomide for NK/T Lymphoma
Recruiting
  • Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type
  • Guangzhou, Guangdong, China
    Department of Medical Oncology, Sun Yat-sen University Cancer Ce
2021-03-12
Mar 12, 2021
T
B-MAD Chemotherapy in Newly-diagnosed Extranodal NK/ T-cell Lymphoma
Recruiting
  • Extranodal NK/T-cell Lymphoma
  • B-MAD chemotherapy
  • Bangkok, Thailand
    King Chulalongkorn Memorial Hospital
2021-04-30
Apr 30, 2021
E
An Expanded Access Program to Provide Sugemalimab for the Treatment of Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (R/R ENKTL)
Available
  • Extranodal NK/T-cell Lymphoma
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
2022-03-18
Mar 18, 2022
I
Efficacy and Safety Evaluation of IBI308 in Patients With Extranodal NK/T Cell Lymphoma Patients - 2020
Completed
Has Results
  • Effect of Drugs
  • Nanjing, Jiangsu, China
    Jiangsu Provincial Hospital
2020-12-20
Dec 20, 2020
B
GPED for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma
Recruiting
  • Extranodal NK/T-cell Lymphoma
  • Beijing, China
    Beijing Tongren Hospital
2021-06-02
Jun 2, 2021
I
Evaluation of Safety and Efficacy of IBI318 Monotherapy for Relapsed/Refractory Extranodal NK/T Cell Lymphoma (Nasal Type) Trial
Recruiting
  • Extranodal NK/T Cell Lymphoma, Nasal Type
  • IBI318(Recombinant human anti-PD1/PD-L1 bispecific antibody)
  • Guangdong, China
    Sun Yat-sen University Cancer Center
2020-12-07
Dec 7, 2020
A
Pembrolizumab in Relapsed or Refractory Extranodal NK/T- Cell Lymphoma, Nasal Type and EBV-associated Diffuse Large B Cell Lymphomas - 2020
Withdrawn
  • Lymphoma
  • Philadelphia, Pennsylvania
    Abramson Cancer Center of the University of Pennsylvania
2021-05-05
May 5, 2021
S
A Phase II Study of Linperlisib (YY-20394) in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma
Not yet recruiting
  • Peripheral T/NK Cell Lymphoma (R/R PTCL)
  • (no location specified)
2022-03-10
Mar 10, 2022
X
GELAD Chemotherapy and Sandwiched Radiotherapy in the Treatment of Stage IE/IIE Natural Killer/T-cell Lymphoma - 2021
Completed
  • Extranodal NK-T-Cell Lymphoma, Nasal Type
  • Shanghai, Shanghai, China
  • +6 more
2021-09-13
Sep 13, 2021
S
Prognostic Nomogram of Extranodal NK/T-cell Lymphoma
Recruiting
  • Extranodal NK/T-cell Lymphoma
    • Guangzhou, Guangdong, China
      Sun Yat-sen University Cancer Center
    2020-09-12
    Sep 12, 2020
    F
    AEDV Registry of Primary Cutaneous Lymphoma
    Recruiting
    • Lymphoma, T-Cell, Cutaneous
    • +5 more
    • Registry of patients (exposure is Cutaneous Lymphoma)
    • Barcelona, Spain
    • +13 more
    2022-03-15
    Mar 15, 2022
    N
    Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma
    Not yet recruiting
    • Adult T-cell Leukemia/Lymphoma
    • +4 more
    • CC-486 (5-azacitidine)
    • +3 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    2022-04-07
    Apr 7, 2022
    K
    Allogeneic Stem Cell Transplantation in Relapsed/Refractory T-, NK/T-cell Lymphomas
    Recruiting
    • T-cell Non-Hodgkin Lymphoma
    • Lymphoma, Extranodal NK-T-Cell
    • Busan, Korea, Republic of
    • +1 more
    2020-09-07
    Sep 7, 2020
    I
    A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type
    Recruiting
    • Extranodal NK/T-cell Lymphoma, Nasal Type
    • Extranodal NK/T-cell Lymphoma
    • Hwasun, Chonnam, Korea, Republic of
    • +2 more
    2020-10-23
    Oct 23, 2020
    S
    A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies
    Not yet recruiting
    • Peripheral T Cell Lymphoma
    • +3 more
    • STI-3031
    • (no location specified)
    2022-03-14
    Mar 14, 2022
    S
    Anti-PD-1 Antibody and Pegaspargase Combined With Radiotherapy in Early-Stage ENKTL
    Not yet recruiting
    • Extranodal NK/T-cell Lymphoma, Nasal Type
    • Guangzhou, Please Select, China
      Sun Yat-sen University Cancer Center
    2020-12-16
    Dec 16, 2020
    Z
    A Prospective Clinical Study of Ruxolitinib and Etoposide Combined With DDGP Regimen (RUE-DDGP) in Induction Therapy of T/NK Cell Lymphoma-associated Hemophagocytic Syndrome.
    Recruiting
    • Hemophagocytic Syndrome
    • T/NK-Cell Lymphoma
    • Ruxolitinib, Etoposide, Dexamethasone, Gemcitabine, Pegaspargase, cis-platinum
    • Zhengzhou, Henan, China
      Oncology Department of The First Affiliated Hospital of Zhengzho
    2021-08-03
    Aug 3, 2021